Notice ID: 3fca19a50da6422c9e851d530af91d68Solicitation
A--PREVENT IDIQ MATO RFP
Archived on March 15, 2023. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 10:00 AM UTC−05:00
- Posted
- September 16, 2024
- Notice type
- Solicitation
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NIH NCI
- Last updated
- Sep 9, 2025
Identifiers
- Solicitation number
- 75N91023R00024
- Notice ID
- 3fca19a50da6422c9e851d530af91d68
Description
Amendment 02 is to issue minor changes to solicitation, 75N91023R00024, for the PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing. See attached for additional details.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75N91023R00024- Pre-Solicitation
- Solicitation
- Awarded
Award typically follows within 30–90 days after the response deadline. (estimate)
- 2×Pre-SolicitationDec 19, 2022
A--PREVENT IDIQ MATO RFP
- 3×
- 4×AwardedFeb 1, 2024
A--PREVENT Preclinical Efficacy & Endpoint Biomarkers
- SolicitationCurrentSep 16, 2024
A--PREVENT IDIQ MATO RFP
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75N91023R00024
Archive Date
Mar 15, 2023
Office Address
Bethesda, MD, 20892